Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer - PubMed (original) (raw)
Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
Zsofia Sztupinszki et al. NPJ Breast Cancer. 2018.
Abstract
The first genomic scar-based homologous recombination deficiency (HRD) measures were produced using SNP arrays. As array-based technology has been largely replaced by next generation sequencing approaches, it has become important to develop algorithms that derive the same type of genomic scar scores from next generation sequencing (whole exome "WXS", whole genome "WGS") data. In order to perform this analysis, we introduce here the scarHRD R package and show that using this method the SNP array-based and next generation sequencing-based derivation of HRD scores show good correlation (Pearson correlation between 0.73 and 0.87 depending on the actual HRD measure) and that the NGS-based HRD scores distinguish similarly well between BRCA mutant and BRCA wild-type cases in a cohort of triple-negative breast cancer patients of the TCGA data set.
Conflict of interest statement
N.J.B., A.C.E., and Zo.S are listed as co-inventors on a patent on telomeric allelic imbalance, which is owned by Children’s Hospital Boston and licensed to Myriad Genetics. The remaining authors declare no competing interests.
Figures
Fig. 1
Correlation between Affymetrix SNP 6.0 array-based and whole exome sequencing-based measurements of homologous recombination deficiency (telomeric allelic imbalance, loss of heterozygosity, large-scale transitions, and the sum of these estimates)
Fig. 2
Distribution of HRD-sum values in BRCA1/2 deficient and in BRCA1/2 intact triple-negative breast cancer samples from TCGA. HRD-sum values were determined with the scarHRD R package
Similar articles
- Using whole-genome sequencing data to derive the homologous recombination deficiency scores.
de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT. de Luca XM, et al. NPJ Breast Cancer. 2020 Aug 7;6:33. doi: 10.1038/s41523-020-0172-0. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32818150 Free PMC article. - Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS. Timms KM, et al. Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x. Breast Cancer Res. 2014. PMID: 25475740 Free PMC article. - Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
Cristescu R, Liu XQ, Arreaza G, Chen C, Albright A, Qiu P, Marton MJ. Cristescu R, et al. BMC Cancer. 2022 Dec 14;22(1):1310. doi: 10.1186/s12885-022-10197-z. BMC Cancer. 2022. PMID: 36517748 Free PMC article. - Biomarkers for Homologous Recombination Deficiency in Cancer.
Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Hoppe MM, et al. J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085. J Natl Cancer Inst. 2018. PMID: 29788099 Review. - Using SAAS-CNV to Detect and Characterize Somatic Copy Number Alterations in Cancer Genomes from Next Generation Sequencing and SNP Array Data.
Zhang Z, Hao K. Zhang Z, et al. Methods Mol Biol. 2018;1833:29-47. doi: 10.1007/978-1-4939-8666-8_2. Methods Mol Biol. 2018. PMID: 30039361 Review.
Cited by
- Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance.
Yoon KA, Kim Y, Jung SY, Ryu JS, Kim KH, Lee EG, Chae H, Kwon Y, Kim J, Park JB, Kong SY. Yoon KA, et al. Exp Mol Med. 2024 Nov 1. doi: 10.1038/s12276-024-01332-w. Online ahead of print. Exp Mol Med. 2024. PMID: 39482530 - Homologous recombination deficiency score is an independent prognostic factor in esophageal squamous cell carcinoma.
Wang Y, Ding B, Tao Y, Huang L, Zhu Q, Gao C, Feng M, Han Y. Wang Y, et al. J Pathol Clin Res. 2024 Nov;10(6):e70007. doi: 10.1002/2056-4538.70007. J Pathol Clin Res. 2024. PMID: 39469984 Free PMC article. - Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types.
Loeffler CML, El Nahhas OSM, Muti HS, Carrero ZI, Seibel T, van Treeck M, Cifci D, Gustav M, Bretz K, Gaisa NT, Lehmann KV, Leary A, Selenica P, Reis-Filho JS, Ortiz-Bruechle N, Kather JN. Loeffler CML, et al. BMC Biol. 2024 Oct 8;22(1):225. doi: 10.1186/s12915-024-02022-9. BMC Biol. 2024. PMID: 39379982 Free PMC article. - DNA damage response in breast cancer and its significant role in guiding novel precise therapies.
Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H, Xie Z, Jiang Y, Wang X, Liu J. Li J, et al. Biomark Res. 2024 Sep 27;12(1):111. doi: 10.1186/s40364-024-00653-2. Biomark Res. 2024. PMID: 39334297 Free PMC article. Review. - Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends.
Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D. Thapa B, et al. Cancer Manag Res. 2024 Sep 17;16:1267-1283. doi: 10.2147/CMAR.S411023. eCollection 2024. Cancer Manag Res. 2024. PMID: 39308935 Free PMC article. Review.
References
- Birkbak NJ, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366–375. doi: 10.1158/2159-8290.CD-11-0206. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials